Who
Thomas Catinazzo
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Relay Therapeutics.
In numbers
- Trades disclosed
- 128
- Buys
- 0
- Sells
- 58
- Bought
- $0
- Sold
- $16.6M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 11 Dec 2020
- Last trade
- 6 Oct 2026
- Last filed
- 8 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Oct 2026filed 8 Oct 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $325K17,511 at $18.58 | filing |
| 6 Oct 2026filed 8 Oct 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,968206 at $19.26 | filing |
| 8 Sep 2026filed 9 Sep 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $336K17,717 at $18.94 | filing |
| 8 Sep 2026filed 9 Sep 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $336K17,717 at $18.94 | filing |
| 14 Aug 2026filed 18 Aug 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $350K17,717 at $19.74 | filing |
| 14 Aug 2026filed 18 Aug 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $350K17,717 at $19.74 | filing |
| 28 Jul 2026filed 30 Jul 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $27K1,459 at $18.61 | filing |
| 28 Jul 2026filed 30 Jul 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $27K1,459 at $18.61 | filing |
| 6 Jul 2026filed 8 Jul 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $331K17,717 at $18.69 | filing |
| 6 Jul 2026filed 8 Jul 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $331K17,717 at $18.69 | filing |
| 22 Jun 2026filed 24 Jun 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $301K17,717 at $17.01 | filing |
| 22 Jun 2026filed 24 Jun 2026 | RLAY Relay Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —51,560 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Code M | $284K56,323 at $5.04 | filing |
| 22 Jun 2026filed 24 Jun 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $956K56,323 at $16.97 | filing |
| 22 Jun 2026filed 24 Jun 2026 | RLAY Relay Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —56,323 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | RLAY Relay Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —61,563 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | RLAY Relay Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —51,560 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Code M | $321K61,563 at $5.22 | filing |
| 22 Jun 2026filed 24 Jun 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.0M61,563 at $16.97 | filing |
| 22 Jun 2026filed 24 Jun 2026 | RLAY Relay TherapeuticsBiotechnology | SEC FORM 4 Code M | $229K51,560 at $4.45 | filing |
News
Head-To-Head Comparison: Krystal Biotech (NASDAQ:KRYS) and Relay Therapeutics (NASDAQ:RLAY)RLAY · tickerreport.com · 11 Oct 2026
0 headlines in the last 90 days name Thomas Catinazzo; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.